Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05479357
Collaborator
(none)
80
2
5.1

Study Details

Study Description

Brief Summary

Comparison between Carbetocin and Oxytocin as prophylaxis against Primary Postpartum Hemorrhage.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Patients will be allocated randomly by simple randomization into either 1- the control group which will be given 10 IU oxytocin intravenously, OR 2- the treatment group which will be given 100 micrograms of carbetocin intravenously.

The trial will be conducted on patients with high risk of developing atonic primary postpartum hemorrhage. The trial will be single blinded. All patients fulfilling the inclusion criteria undergoing elective Caesarean section will be approached by the treating physician and will be asked to participate in the study. An informed written consent will be taken from each patient. The data collected will include base line characteristics such as age, parity, body mass index, the risk for Postpartum hemorrhage in each patient, amount of blood loss, blood units given, complete blood picture (pre and post operative) and coagulation profile.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized Clinical Trial (Simple randomization)Randomized Clinical Trial (Simple randomization)
Masking:
Single (Participant)
Masking Description:
Patient will be blinded to the drug to be used
Primary Purpose:
Prevention
Official Title:
Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage in High-risk Patients in Sohag University Hospital: A Randomized Controlled Clinical Trial
Anticipated Study Start Date :
Jul 28, 2022
Anticipated Primary Completion Date :
Dec 30, 2022
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Oxytocin

the control group will be given 10 iu intravenously.

Drug: Oxytocin
10 iu will be given intravenously.

Active Comparator: Carbetocin

the treatment group will be given 100 microgram intravenously.

Drug: Carbetocin
100 micrograms will be given intravenously.

Outcome Measures

Primary Outcome Measures

  1. Amount of Postpartum Hemorrhage [First 24 hours after Delivery]

    Amount of Blood Loss in milliliters. Pre-operative patient's Hemoglobin (Hb) level and 24 hours post-operative will be assessed to quantify amount of blood loss. Additionally, all towels prepared for CS will weighed, and the weight will be marked on each pack before autoclaving. All towels (used and unused) will be weighed again after use, and a difference of 1 gm will be considered as equivalent to 1 mL of absorbed blood.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • • High risk patients for post-partum hemorrhage who will subjected to Caeserean section either elective or in labour at or after 36 weeks of gestation. This should include one or more of the following:
  1. History of postpartum hemorrhage.

  2. Delivery of a macrosomic baby (> 4000 g).

  3. Multiple gestation.

  4. Polyhydramnios.

  5. Grand Multiparity.

  6. Interstitial or submucous fibroid. (Single larger than 4 cm or Multiple myomata)

  7. Chorioamnionitis.

Exclusion Criteria:
  • • Patients without high risk for post-partum hemorrhage.

  • Patients at high risk for postpartum hemorrhage but will deliver vaginally.

  • Patients with medical disorders complicating pregnancy.

  • Patients with coagulation defects.

  • Preterm pregnancies.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sohag University

Investigators

  • Principal Investigator: Magdy M Ameen, MD, Faculty of Medicine, Sohag University
  • Principal Investigator: Ahmed T Ahmed, MD, Faculty of Medicine, Sohag University
  • Principal Investigator: Amr O Abdelkareem, MD, Faculty of Medicine, Sohag University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Eman Mahmoud Sabry, Dr., Sohag University
ClinicalTrials.gov Identifier:
NCT05479357
Other Study ID Numbers:
  • Soh-Med-22-07-02
First Posted:
Jul 29, 2022
Last Update Posted:
Aug 2, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Eman Mahmoud Sabry, Dr., Sohag University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2022